45 documents found, page 1 of 5
Strategies for overcoming toxicity and resistance in melanoma progression and i...
Maria-Engler, Silvya Stuchi
Gliotoxin and its potential cytotoxicity against NRAS-mutated melanoma
Maria-Engler, Silvya Stuchi
Copper (II) complex as a potential treatment to overcome BRAF inhibitor resista...
Maria-Engler, Silvya Stuchi
Cellular spheroids as a platform for toxicogenomic assays in cancer
Maria-Engler, Silvya Stuchi
Bioprinted and manual human epidermis reconstruction: a compared performance fo...
Maria-Engler, Silvya Stuchi
Redox related proteins in melanoma progression
Maria-Engler, Silvya Stuchi
Quercetin increases mitochondrial proteins (VDAC and SDH) and downmodulates AXL...
Maria-Engler, Silvya Stuchi
3-bromopyruvate suppresses the malignant phenotype of vemurafenib-resistant mel...
Vital, Patrik da Silva; Bonatelli, Murilo; Dias, Marina Pereira; Salis, Larissa Vedovato Vilela de; Pinto, Mariana Tomazini; Baltazar, Fátima(1) <i>BRAF</i> mutations are associated with high mortality and are a substantial factor in therapeutic decisions. Therapies targeting <i>BRAF</i>-mutated tumors, such as vemurafenib (PLX), have significantly improved the overall survival of melanoma patients. However, patient relapse and low response rates remain challenging, even with contemporary therapeutic alternatives. Highly proliferative tumors often r...
TOP1 modulation during melanoma progression and in adaptative resistance to BRA...
Maria-Engler, Silvya Stuchi